AbCellera Biologics Inc.
ABCL
$2.39
$0.052.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.05M | 6.51M | 7.32M | 9.95M | 9.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.05M | 6.51M | 7.32M | 9.95M | 9.18M |
| Cost of Revenue | 46.08M | 40.97M | 40.93M | 39.29M | 48.62M |
| Gross Profit | -41.03M | -34.46M | -33.60M | -29.33M | -39.44M |
| SG&A Expenses | 19.16M | 22.28M | 23.33M | 20.72M | 19.07M |
| Depreciation & Amortization | -19.44M | 36.92M | 36.52M | 4.84M | 7.54M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.81M | 100.17M | 100.78M | 64.85M | 75.23M |
| Operating Income | -40.76M | -93.66M | -93.45M | -54.89M | -66.05M |
| Income Before Tax | -46.83M | -62.63M | -48.19M | -42.75M | -48.60M |
| Income Tax Expenses | -12.62M | -11.53M | -11.26M | -2.14M | -1.45M |
| Earnings from Continuing Operations | -34.21M | -51.11M | -36.93M | -40.61M | -47.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.21M | -51.11M | -36.93M | -40.61M | -47.15M |
| EBIT | -40.76M | -93.66M | -93.45M | -54.89M | -66.05M |
| EBITDA | -26.04M | -56.74M | -56.93M | -50.05M | -58.52M |
| EPS Basic | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 |
| Normalized Basic EPS | -0.06 | -0.17 | -0.10 | -0.10 | -0.12 |
| EPS Diluted | -0.12 | -0.17 | -0.13 | -0.14 | -0.17 |
| Normalized Diluted EPS | -0.06 | -0.17 | -0.10 | -0.10 | -0.12 |
| Average Basic Shares Outstanding | 295.52M | 294.85M | 294.22M | 292.72M | 290.41M |
| Average Diluted Shares Outstanding | 295.52M | 294.85M | 294.22M | 292.72M | 290.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
